QGel is a biomedical technology company specialized in organoid applications and solutions.
Our proprietary hydrogel technology, designed to mimic the microenvironment surrounding cells inside the human body, is capable of growing patient cells from biopsy outside of the body, while maintaining the key biomarkers from the patient’s originating tissue.
This novel innovation provides the ability to test many potential anti-cancer therapies on patient cancer avatars, ex vivo, to observe how each tumor clone responds to each therapy option, giving oncologists insight to expected patient response.
Every patient is unique.
The future success of health care will depend on the ability to accurately model the complex nature of patient biology in order to identify which drug regimens will work for each individual patient.
At QGel, we seek to accelerate this development.
QGel is currently working with leading cancer centers to bring its proprietary precision medicine technology closer to patients. Based on successfully completed proof-of-concept studies, we are now designing clinical trials to receive regulatory medical device approval for drug decision making for a variety of cancers.
Fill out Survey below
to learn more about clinical studies with QGel